Smith & Nephew announces European launch of new PICO™ 7 Single Use Negative Pressure Wound Therapy System

Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, is pleased to announce the European launch of the new PICO 7 Single Use Negative Pressure Wound Therapy System (sNPWT).

PICO 7 delivers a number of enhancements which benefit both the clinical effectiveness and patient experience.

Clinically PICO 7 delivers a more efficient vacuum and superior leak management¹, designed to support improved application on anatomically challenging areas where it is traditionally more difficult to achieve and maintain a seal. It also includes an industry-first dressing-full indicator for sNPWT devices, which is intended to reduce unnecessary dressing changes and wastage.

For the patient, PICO 7 is more than 25% quieter than the previous version² making it less intrusive, of particular value when the patient is outside the home or sleeping. There is also a new user interface to simplify patient operation and a belt clip to improve portability.

Dr Theresa Hurd, RN, MScN, PhD said “Having tried PICO 7 I can confirm that it has real clinical, economic and patient benefits. With the new PICO 7 system I can be confident that we will experience fewer leaks and can hence reduce the number of nurse interventions, reducing costs and improving care.”

PICO 7 is designed for patients at risk of poor healing, and has been shown to help minimise the failures of healing that may lead to infection and/or dehiscence³. It is suitable for use in both a hospital and community setting and approved for a number of indications, including surgically closed incision sites. A recently published meta-analysis, demonstrated the efficacy of PICO used prophylactically for SSI reduction in closed surgical incisions compared with standard care³.

“With PICO we revolutionised the use of negative pressure wound therapy, making a treatment previously only available in a hospital inpatient setting available to outpatients in a clinical and cost effective portable solution,” said Paolo Di Vincenzo, Smith & Nephew’s SVP of Advanced Wound Management. “With PICO 7 we have delivered significant design improvements that contribute to improved patient outcomes, patient management and HCP efficiency, keeping Smith & Nephew at the forefront of delivering pioneering portable negative pressure solutions.”

It was confirmed that PICO 7 met all relevant European requirements on Wednesday 24th January 2018.

Enquiries

Media

Dave Snyder
+1 (978) 749-1440
Smith & Nephew

Investors / Analysts

Ingeborg Øie
+44 (0)20 7960 2285
Smith & Nephew

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to supporting healthcare professionals in their daily efforts to improve the lives of their patients. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has more than 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.}

^{◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.}